Earnings ·
AVITA Medical raises full-year revenue guidance to $92M-$94M after Q3 sales jump 53% to $26.1M
AVHHLAVITA Medical, Inc.
AVITA Medical reported third-quarter total revenue of $26.1 million, a 53% increase from the prior year and a 20% sequential rise, driven by strong RECELL adoption and growing Cohealyx sales. Gross margin expanded to 84.0%, while operating expenses remained flat at $24.6 million despite performance-based compensation increases. The company raised its full-year 2026 revenue guidance to the $92 million to $94 million range, up from the previous estimate of $86 million to $89 million, and reaffirmed expectations for cash flow breakeven in Q4. Additionally, AVITA Medical drew down an additional $10 million tranche under its credit facility with Perceptive Advisors LLC after achieving a trailing twelve-month revenue milestone of $85 million, strengthening its liquidity position.